Unlocking the Potential of CCDC92B: A novel Drug Target and Biomarker

Target Name: CCDC92B

NCBI ID: G101928991

CCDC92B

Other Name(s): coiled-coil domain containing 92B | CCDC92B variant 1 | Coiled-coil domain-containing 92B (isoform 1) | Coiled-coil domain containing 92B, transcript variant 1

Unlocking the Potential of CCDC92B: A novel Drug Target and Biomarker

The search for new drug targets and biomarkers has been a critical aspect of drug development for several decades. One of the promising targets in this field is the coiled-coil domain containing 92B (CCDC92B), which has been identified as a potential drug target and biomarker. In this article, we will explore the biology of CCDC92B, its potential as a drug target, and its potential as a biomarker for various diseases.

The Importance of CCDC92B

CCDC92B is a 92-kDa protein that is expressed in various tissues and cells in the human body. It is characterized by a unique coiled-coil structure, which gives it its unique name. The coiled-coil structure of CCDC92B allows it to form a stable interaction with various protein partners, including transcription factors, DNA-binding proteins, and cytoplasmic proteins.

In recent years, several studies have highlighted the potential of CCDC92B as a drug target. Its unique coiled-coil structure and its expression in various tissues make it an attractive target for drug developers. Additionally, its expression has been implicated in several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

Potential Applications of CCDC92B as a Drug Target

CDC92B has been shown to play a critical role in several cellular processes, including cell signaling, DNA replication, and apoptosis. Its unique coiled-coil structure and its interaction with various protein partners make it an attractive target for drug developers. Several studies have shown that CCDC92B can be targeted by small molecules, antibodies, and other therapeutic agents.

One of the most promising strategies for targeting CCDC92B is the use of small molecules. Small molecules can interact with CCDC92B's coiled-coil structure and disrupt its function. Several studies have shown that CCDC92B is sensitive to small molecules, including inhibitors of tyrosination, inhibitors of protein-protein interactions, and inhibitors of DNA-protein binding.

Another approach to targeting CCDC92B is the use of antibodies. antibodies can interact with CCDC92B's coiled-coil structure and disrupt its function. Several studies have shown that CCDC92B is a good target for antibodies, including monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), and polyvalent antibodies.

Potential Applications of CCDC92B as a Biomarker

CCDC92B has also been shown to be a potential biomarker for several diseases. Its unique coiled-coil structure and its expression in various tissues make it an attractive target for biomarker development.

One of the most promising applications of CCDC92B as a biomarker is its potential to serve as a diagnostic marker for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Several studies have shown that CCDC92B is expressed in the brains of individuals with neurodegenerative diseases, and its levels are decreased in the brains of individuals with these diseases. Additionally, CCDC92B has been shown to be a potential therapeutic target for neurodegenerative diseases.

Another potential application of CCDC92B as a biomarker is its potential to serve as a diagnostic marker for cancer. Several studies have shown that CCDC92B is expressed in various tissues and cells of individuals with cancer, and its levels are often increased in these tissues. Additionally, CCDC92B has been shown to be a potential therapeutic target for cancer.

Conclusion

In conclusion, CCDC92B is a unique protein that has

Protein Name: Coiled-coil Domain Containing 92B

The "CCDC92B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC92B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets